Highly selective antibiotics may fight highly resistant human pathogens
Antibiotics (literally 'against life') kill bacteria. As our bodies are host to many 'good' bacteria, selective antibiotics are needed. Ribosomes are the site of protein synthesis and the target of novel therapeutics under development by NEXTER. The key is in targeting certain portions of ribosomes that are specific to certain species of bacteria. Using this strategy, scientists have stopped the growth of a multi-drug resistant strain of Staphylococcus aureus (S. aureus), an important human pathogen causing infection in both clinical and community settings. Further, these synthetic therapeutics are degradable meaning they will decrease environmental contamination, further reducing the development of resistant strains. The team is now targeting other pathogens and plans to take the pioneering technology to market soon.
Fields of science
Call for proposal
See other projects for this call